Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

Alden, SL; Lim, M; Kao, C; Shu, D; Singal, AG; Noonan, A; Griffith, P; Baretti, M; Ho, WJ; Kamel, I; Yarchoan, M; Hsiehchen, D

Hsiehchen, D (通讯作者)，Univ Texas SouthWestern Med Ctr Dallas, Dallas, TX 75390 USA.;Yarchoan, M (通讯作者)，Johns Hopkins Univ, Baltimore, MD 21287 USA.

CANCER RESEARCH COMMUNICATIONS, 2023; 3 (7): 1312

Abstract

Combination anti-PD-(L)1/CTLA-4 blockade is approved in patients with hepatocellular carcinoma (HCC) in the first-line setting or after sorafenib, but......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索